JP2006512891A - 糸状菌における機能性抗体の生産 - Google Patents

糸状菌における機能性抗体の生産 Download PDF

Info

Publication number
JP2006512891A
JP2006512891A JP2003586327A JP2003586327A JP2006512891A JP 2006512891 A JP2006512891 A JP 2006512891A JP 2003586327 A JP2003586327 A JP 2003586327A JP 2003586327 A JP2003586327 A JP 2003586327A JP 2006512891 A JP2006512891 A JP 2006512891A
Authority
JP
Japan
Prior art keywords
nucleic acid
monoclonal antibody
immunoglobulin
fusion
glucoamylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003586327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512891A5 (enExample
Inventor
パワー、スコット・ディー
ワン、ホアミン
ワード、マイケル
Original Assignee
ジェネンコー・インターナショナル・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29255585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006512891(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジェネンコー・インターナショナル・インク filed Critical ジェネンコー・インターナショナル・インク
Publication of JP2006512891A publication Critical patent/JP2006512891A/ja
Publication of JP2006512891A5 publication Critical patent/JP2006512891A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2003586327A 2002-04-18 2003-04-17 糸状菌における機能性抗体の生産 Pending JP2006512891A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37388902P 2002-04-18 2002-04-18
US41153702P 2002-09-18 2002-09-18
US41154002P 2002-09-18 2002-09-18
US45213403P 2003-03-04 2003-03-04
PCT/US2003/012246 WO2003089614A2 (en) 2002-04-18 2003-04-17 Production of functional antibodies in filamentous fungi

Publications (2)

Publication Number Publication Date
JP2006512891A true JP2006512891A (ja) 2006-04-20
JP2006512891A5 JP2006512891A5 (enExample) 2006-06-08

Family

ID=29255585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003586327A Pending JP2006512891A (ja) 2002-04-18 2003-04-17 糸状菌における機能性抗体の生産

Country Status (6)

Country Link
US (2) US20040018573A1 (enExample)
EP (1) EP1495055B1 (enExample)
JP (1) JP2006512891A (enExample)
AU (1) AU2003222664A1 (enExample)
DK (1) DK1495055T3 (enExample)
WO (1) WO2003089614A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009060804A (ja) * 2007-09-04 2009-03-26 National Research Inst Of Brewing ピヒア属酵母において異種タンパク質を高分泌させる方法
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
KR20200066340A (ko) 2017-10-10 2020-06-09 아지노모토 가부시키가이샤 단백질의 제조 방법
WO2021251383A1 (ja) 2020-06-11 2021-12-16 味の素株式会社 タンパク質の製造法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018573A1 (en) * 2002-04-18 2004-01-29 Power Scott D Production of functional antibodies in filamentous fungi
US7208585B2 (en) * 2002-09-18 2007-04-24 Genencor International, Inc. Protein purification
DK1578774T3 (da) * 2002-09-18 2014-02-03 Danisco Us Inc Oprensning af immunoglobuliner
KR20060069825A (ko) * 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 cdr 폴리펩티드 서열
WO2005049649A1 (en) * 2003-11-05 2005-06-02 Ares Trading S.A. Process for the purification of il-18 binding protein
CA2553731A1 (en) * 2004-01-21 2005-08-04 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
ATE514770T1 (de) * 2005-10-17 2011-07-15 Novozymes As Verwendung von pilzmutanten zur expression von antikörpern
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
US20080026376A1 (en) 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
WO2008057637A2 (en) * 2006-07-21 2008-05-15 Novozymes, Inc. Methods of increasing secretion of polypeptides having biological activity
EP2102240A2 (en) * 2007-01-05 2009-09-23 Novozymes A/S Overexpression of the chaperone bip in a heterokaryon
WO2008115596A2 (en) * 2007-03-21 2008-09-25 Danisco Us, Inc., Genencor Division Over expression of foldases and chaperones improves protein production
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
US20100273215A1 (en) * 2007-12-21 2010-10-28 Anna Cornelia Hendrika Van Hautum Secretion Yield of a Protein of Interest by in vivo Proteolytic Processing of a Multimeric Precursor
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
KR20110031369A (ko) 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
EP2427488A1 (en) * 2009-05-07 2012-03-14 Novozymes Biopharma DK A/S Method of controlling o-linked glycosylation of antibodies
EP2427489B1 (en) 2009-05-07 2015-04-22 Novozymes Biopharma DK A/S Method of controlling o-linked glycosylation of antibodies
WO2010141468A1 (en) * 2009-06-01 2010-12-09 Way Jeffrey C Methods and molecules for yield improvement involving metabolic engineering
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2601218A4 (en) 2010-08-03 2015-02-18 Abbvie Inc VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン
AU2013207165B2 (en) 2012-01-05 2018-10-04 Glykos Finland Oy Protease deficient filamentous fungal cells and methods of use thereof
KR101505157B1 (ko) 2012-05-08 2015-03-24 주식회사 종근당 항―ErbB2 항체 변이체
EP2852610B1 (en) 2012-05-23 2018-07-11 Glykos Finland Oy Production of fucosylated glycoproteins
RU2636043C2 (ru) 2012-11-01 2017-11-17 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
WO2014152145A1 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Methods for producing antibodies
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
CA2916905A1 (en) 2013-07-10 2015-01-15 Novartis Ag Multiple proteases deficient filamentous fungal cells and methods of use thereof
CN108064266A (zh) 2014-07-21 2018-05-22 格利科斯芬兰公司 在丝状真菌中具有哺乳动物样n-聚糖的糖蛋白的制备
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ErbB2 항체 변이체
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN107674900B (zh) * 2017-06-12 2021-05-14 诺利如一(安阳)生物科技有限公司 一种采用串联膜浓缩大豆肽的工艺方法
KR20200132938A (ko) 2018-03-15 2020-11-25 추가이 세이야쿠 가부시키가이샤 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4525615A2 (en) 2022-05-14 2025-03-26 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
EP4574840A1 (en) 2022-08-15 2025-06-25 The University of Tokyo Method for producing immunoglobulin or multimer immunoglobulin using filamentous fungus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3009104C2 (de) * 1980-03-10 1990-10-04 Odenwald-Chemie GmbH, 6901 Schönau Verwendung eines Epoxydharzes zur Herstellung von feuerhemmenden Schichten oder Überzügen und Verfahren zur Herstellung derselben
CA1338400C (en) 1983-08-31 1996-06-18 David H. Gelfand Recombinant fungal cellulases
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US20020061560A1 (en) * 1985-08-29 2002-05-23 Genencor, Inc. DNA sequences, vectors, and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
ATE117020T1 (de) 1985-08-29 1995-01-15 Genencor Int Expression von heterologen polypeptiden in filamentösen pilzen, verfahren zu deren herstellung und vektoren zu deren herstellung.
US5364770A (en) * 1985-08-29 1994-11-15 Genencor International Inc. Heterologous polypeptides expressed in aspergillus
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5610034A (en) * 1987-04-29 1997-03-11 Alko Group Ltd. Immunoglobulin production by trichoderma
US5218093A (en) * 1989-03-01 1993-06-08 Allelix Biopharmaceuticals, Inc. EGF variants and pharmaceutical use thereof
GB9215540D0 (en) * 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
ATE204325T1 (de) * 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5683899A (en) * 1994-02-03 1997-11-04 University Of Hawaii Methods and compositions for combinatorial-based discovery of new multimeric molecules
US5643745A (en) * 1994-02-03 1997-07-01 University Of Hawaii Heterologous dimeric proteins produced in heterokaryons
US6300114B1 (en) * 1994-07-29 2001-10-09 Rohm Enzyme Finland Oy Sequences of xylanase and xylanase expression vectors
AU1750697A (en) * 1996-01-19 1997-08-11 Novo Nordisk Biotech, Inc. Morphological mutants of filamentous fungi
US6140113A (en) * 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US6265204B1 (en) * 1997-01-17 2001-07-24 Genencor International, Inc. DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi
GB9703406D0 (en) * 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6232112B1 (en) * 1997-11-24 2001-05-15 Flinders Technologies Pty Ltd Of Flinders University Reagents and methods for diversification of DNA
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PL199659B1 (pl) * 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
US20010036647A1 (en) 1998-10-22 2001-11-01 Prabhakara V. Choudary Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
US6767701B1 (en) * 1998-10-26 2004-07-27 Novozymes A/S Methods of constructing and screening a DNA library of interest in filamentous fungal cells
WO2000025574A1 (en) * 1998-10-30 2000-05-11 Thomas Jefferson University Production of biomedical peptides and proteins in plants using plant virus vectors
US7094571B2 (en) * 2000-10-27 2006-08-22 The Board Of Regents Of The University Of Texas System Combinatorial protein library screening by periplasmic expression
US7083945B1 (en) * 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
DE60138927D1 (de) * 2000-11-07 2009-07-16 Zymogenetics Inc Menschlicher rezeptor für tumor necrosis factor
DE60126130T2 (de) * 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
DE60234202D1 (de) * 2001-05-24 2009-12-10 Zymogenetics Inc Taci-immunoglobulin-fusionsproteine
US20040018573A1 (en) * 2002-04-18 2004-01-29 Power Scott D Production of functional antibodies in filamentous fungi
US7611866B2 (en) * 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Selection of bacterial inner-membrane anchor polypeptides
DE60332957D1 (de) * 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
EP1588166A4 (en) * 2003-01-09 2007-06-27 Macrogenics Inc VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
US20060024782A1 (en) * 2004-01-21 2006-02-02 Novozymes A/S Production of a monoclonal antibody in a heterokaryon filamentous fungus or in a filamentous fungal host cell
CA2560074A1 (en) * 2004-03-18 2005-11-03 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
CA2671264C (en) * 2006-11-30 2015-11-24 Research Development Foundation Improved immunoglobulin libraries
WO2008137475A2 (en) * 2007-05-01 2008-11-13 Research Development Foundation Immunoglobulin fc libraries

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009060804A (ja) * 2007-09-04 2009-03-26 National Research Inst Of Brewing ピヒア属酵母において異種タンパク質を高分泌させる方法
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
KR20200066340A (ko) 2017-10-10 2020-06-09 아지노모토 가부시키가이샤 단백질의 제조 방법
US11746342B2 (en) 2017-10-10 2023-09-05 Ajinomoto Co., Inc. Method for manufacturing protein
WO2021251383A1 (ja) 2020-06-11 2021-12-16 味の素株式会社 タンパク質の製造法
KR20230023751A (ko) 2020-06-11 2023-02-17 아지노모토 가부시키가이샤 단백질의 제조법
US12492370B2 (en) 2020-06-11 2025-12-09 Ajinomoto Co., Inc. Method for producing protein using a Talaromyces cellulolyticus strain having reduced activity of PEP4

Also Published As

Publication number Publication date
AU2003222664A8 (en) 2003-11-03
EP1495055B1 (en) 2013-08-14
EP1495055A2 (en) 2005-01-12
US20040018573A1 (en) 2004-01-29
DK1495055T3 (da) 2013-11-11
US7977067B2 (en) 2011-07-12
WO2003089614A2 (en) 2003-10-30
WO2003089614A3 (en) 2004-02-26
US20050158825A1 (en) 2005-07-21
EP1495055A4 (en) 2007-08-01
AU2003222664A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
EP1495055B1 (en) Production of functional antibodies in filamentous fungi
JP6840908B1 (ja) エフェクター機能が除去されたIgG1 Fc変異体
EP2542575B1 (en) Expression of monoclonal antibodies in tetrahymena
JP6475167B2 (ja) ジスルフィド結合した多価mhcクラスiを含む多機能タンパク質
Ward et al. Characterization of humanized antibodies secreted by Aspergillus niger
US20180291103A1 (en) Single domain antibody and derivative proteins thereof against programmed death-ligand (pdl1)
US20190169309A1 (en) Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class 1 compromising multi-function proteins
US8518667B2 (en) KEX2 cleavage regions of recombinant fusion proteins
CN110229235A (zh) 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
JP2007535913A (ja) ヘテロカリオン菌類又は菌類宿主細胞におけるモノクローナル抗体の生成
JP2008538926A (ja) 切断可能なリンカーを有する一本鎖抗体
CN113474372A (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
JP2021514625A (ja) 抗muc1抗体およびil−15を含む融合タンパク質構築物
WO2021259304A1 (en) Antibodies and methods for treating claudin-associated diseases
US8198046B2 (en) KEX2 cleavage regions of recombinant fusion proteins
EP3019601B1 (en) Methods for producing sialylated therapeutic proteins
US20250206824A1 (en) GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
US20250154262A1 (en) Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
US20250002593A1 (en) Novel anti-il-36r antibodies
Jung Engineering of aglycosylated antibody Fc for effector functions

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090406

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811